Podcast 683: Zofran vs. Haldol for Cannabinoid Hyperemesis Syndrome

<p><strong>Contributor:  Jared Scott, MD</strong></p> <p><strong>Educational Pearls:</strong></p> <ul> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Around 30 patients with cannabinoid hyperemesis syndrome (CHS) randomized treatment in three arms with 8mg Zofran, Haldol 0.05 mg/kg, and Haldol 0.1 mg/kg</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Haldol arms performed better on all measures compared to Zofran</span></li> <li style="font-weight: 400;" aria-level="1"><span style= "font-weight: 400;">Extrapyramidal symptoms were significantly higher in the Haldol group than Zofran, especially the high-dose Haldol group</span></li> </ul> <p><strong>References</strong></p> <p><span style="font-weight: 400;">Ruberto AJ, Sivilotti MLA, Forrester S, Hall AK, Crawford FM, Day AG. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. Ann Emerg Med. 2021;77(6):613-619. doi:10.1016/j.annemergmed.2020.08.021</span></p> <p><em><span style="font-weight: 400;">Summarized by John Spartz, MS4 | Edited by Erik Verzemnieks, MD</span></em></p> <p> </p> <p><span style="font-weight: 400;">The Emergency Medical Minute is excited to announce that we are now offering</span> <em><span style="font-weight: 400;">AMA PRA Category 1 credits™</span></em> <span style="font-weight: 400;">via online course modules. To access these and for more information, visit our website at</span> <a href= "http://www.emergencymedicalminute.com/cme-courses"><span style= "font-weight: 400;">www.emergencymedicalminute.com/cme-courses/</span></a> <span style="font-weight: 400;">and create an account. </span></p> <p><a href= "https://www.paypal.com/donate?token=6bIZ91UwjZALMiRLAEcQYYPHyLILwbivQwgtGl3JzaB6oGAQK1B2nrGSGvrS-g7zJApXzVlWIO-lmLfB"> <span style="font-weight: 400;">Donate to EMM today!</span></a></p> <p><br /> <br /></p>